Waldencast has completed the divestiture of Obagi Medical to Bridgepoint for up to $460 million, representing a deliberate portfolio rationalization move. The transaction enables the company to strengthen its balance sheet while streamlining its business focus toward higher-growth opportunities.
This strategic separation signals management confidence in Milk Makeup as the primary growth engine and suggests confidence in Bridgepoint's ability to maximize value in the dermatological skincare segment independently. The transaction removes a non-core asset and generates capital for debt reduction or reinvestment in the core beauty brand.
The deal structure includes earnout provisions tied to closing adjustments (cash, debt, working capital, and expenses), which creates potential upside or downside depending on transaction settlement dynamics. This is typical in mid-market PE transactions and reflects negotiated risk allocation between buyer and seller.
Sector implication: The health care and consumer discretionary intersection benefits from portfolio clarity and focused capital allocation. WALD now operates with clearer market positioning, while Bridgepoint gains a standalone dermatology asset in an attractive category—positioning both entities for distinct growth trajectories in skincare and aesthetics markets.